+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Liver Failure (Hepatic Insufficiency) - Pipeline Drugs and Companies, Q2 2019

  • ID: 4762902
  • Report
  • April 2019
  • Region: Global
  • 90 pages
  • VPA Research


  • AVM Biotechnology LLC
  • HepaRegeniX GmbH
  • Martin Pharmaceuticals
  • Mylan NV
  • PledPharma AB
  • Proterris Inc

Liver Failure (Hepatic Insufficiency) pipeline research report is a part of our 300+ Pharmaceutical and Healthcare disease pipeline report series. It provides detailed insights into Liver Failure (Hepatic Insufficiency) R&D activities including pipeline candidates, grants, developments, investments, technological advancements, and progress.

Extensive Coverage of Pipeline Candidates

The Liver Failure (Hepatic Insufficiency) report covers all the pre-clinical compounds and clinical compounds under evaluation for treatment of Liver Failure (Hepatic Insufficiency) as of 2019. All preclinical, research, discovery, pre registration, phase 1, phase 2, and phase 3 trials active are included in the study.

Over 10 descriptive details provided for each Pipeline Product

Complete analysis of therapeutics for treatment of Liver Failure (Hepatic Insufficiency) with details of current status of development, pipeline phase, drug target, mechanism of action (MoA), route of administration (RoA), participating companies, originator, collaborators and molecule type are included. The study also covers the historic developments, pharmacological action and recent developments associated with each drug.

Companies participating in Liver Failure (Hepatic Insufficiency) pipeline Profiled in detail

Key players actively participating in Liver Failure (Hepatic Insufficiency) pipeline are profiled along with their R&D progress in Liver Failure (Hepatic Insufficiency) treatment are provided. Companies /Universities /Institutes participating as originators, collaborators, licensors, investors, and marketing or developing companies are detailed in the report. Further, for all the developing companies, detailed profile is also provided.

Information Sourced from in-house Proprietary Databases

The report is developed using information from in-house database developed over years through daily updates from company reports, websites, events, conferences, news, announcements, clinical trial registries, regulatory authorities, universities and industry associations.

Report assists users in taking actionable steps

Liver Failure (Hepatic Insufficiency) pipeline report enables users to gain clear understanding into large and small companies participating in the pipeline and detailed insights into their product portfolio. The guide presents also available opportunities for new business in Liver Failure (Hepatic Insufficiency) treatment pipeline.

The report includes:
  • The research work provides comprehensive overview of Liver Failure (Hepatic Insufficiency) pipeline and treatment landscape
  • Complete list of drug candidates from discovery to pre-registration phases are analyzed
  • Companies and universities participating in the pipeline are analyzed in detail along with their drug development product portfolio
  • Detailed drug profiles of Liver Failure (Hepatic Insufficiency) pipeline compounds including status, phase, mechanism of action, route of administration, originators, licensing and collaborating companies, grants, technological advancements and investments are detailed
  • Research and Development progress and trial details, results wherever available, are also included in the Liver Failure (Hepatic Insufficiency) pipeline study
  • All recent news and developments related to Liver Failure (Hepatic Insufficiency) drugs are provided
Note: Product cover images may vary from those shown


  • AVM Biotechnology LLC
  • HepaRegeniX GmbH
  • Martin Pharmaceuticals
  • Mylan NV
  • PledPharma AB
  • Proterris Inc
1. Introduction
1.1. Pipeline Snapshot, 2019
1.2. Overview Pipeline Activities in 2019

2. Liver Failure (Hepatic Insufficiency) Disease Overview

3. Liver Failure (Hepatic Insufficiency) R&D Pipeline Trends
3.1. Pipeline Drugs under development by phase, 2019
3.2. Pipeline Drugs by Mechanism of Action, 2019
3.3. Pipeline Drugs by Route of Administration, 2019
3.4. Pipeline Drugs by Company, 2019
3.5. Pipeline Drugs by Molecule Type, 2019

4. Liver Failure (Hepatic Insufficiency) Pre-clinical and Discovery Phase Drug Profiles
4.1. Drug Name/Alternative Names
4.2. Originator
4.3. Licensor/Developer/Collaborators
4.4. Class
4.5. Mechanism of Action
4.6. Route of Administration
4.7. Orphan Drug Status
4.8. New Molecular Entity
4.9. Current Status
4.10. Trial Landscape
4.11. Development History

5. Liver Failure (Hepatic Insufficiency) Clinical Phase Drug Profiles
5.1. Drug Name/Alternative Names
5.2. Originator
5.3. Licensor/Developer/Collaborators
5.4. Class
5.5. Mechanism of Action
5.6. Route of Administration
5.7. Orphan Drug Status
5.8. New Molecular Entity
5.9. Current Status
5.10. Trial Landscape
5.11. Development History

6. Company Profiles
6.1. Liver Failure (Hepatic Insufficiency) companies
6.1.1. Business Profile
6.1.2. Pipeline Products
6.1.3. Liver Failure (Hepatic Insufficiency) Activities

7. Recent News Landscape

8. Appendix
8.1. Sources and Research Methodology
8.2. Publisher Expertise
8.3. Database and Custom Services
Note: Product cover images may vary from those shown
  • AVM Biotechnology LLC
  • Celgene Corp
  • Cell2B Advanced Therapeutics SA
  • Daewoong Pharmaceutical Co Ltd
  • HepaRegeniX GmbH
  • Immune Pharmaceuticals Inc
  • MallInckrodt Plc
  • Martin Pharmaceuticals
  • Mina Therapeutics
  • Mylan NV
  • Novartis AG
  • PledPharma AB
  • Promethera Biosciences
  • Proterris Inc
  • Steminent Biotherapeutics Inc
  • Synlogic Inc
  • Takeda Pharmaceutical Co Ltd
  • Therapure Biopharma
  • Unicyte AG
  • Versantis AG
  • Vital Therapies Inc
  • Xenexus Pharmaceuticals
Note: Product cover images may vary from those shown